Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s share price reached a new 52-week high on Thursday . The stock traded as high as $4.66 and last traded at $4.56, with a volume of 1654 shares trading hands. The stock had previously closed at $4.39.
The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 3.66.
In other news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $3.00, for a total value of $30,000.00. Following the sale, the director now directly owns 909,827 shares of the company’s stock, valued at approximately $2,729,481. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 30,000 shares of company stock worth $102,100 over the last three months. Insiders own 13.78% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/11/10/imprimis-pharmaceuticals-immy-hits-new-1-year-high-at-4-66.html.
About Imprimis Pharmaceuticals (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.